Table 1.

Phase I/II Studies Using Various Combinations of Therapy

VEGFR Inhibitor	VEGF Inhibitor	mTOR Inhibitor	Dose/Toxicity	Reference
Sunitinib	—	Temsirolimus	Sunitinib: 25 mg Temsirolimus: 15 mg Intolerable	Patel et al.109
Sunitinib	—	Everolimus	Sunitinib: 37.5 mg Everolimus: 20 mg	Kroog et al.161
Sunitinib	Bevacizumab		Intolerable	Feldman et al.162
—	Bevacizumab	Temsirolimus	Bevacizumab: 10 mg Temsirolimus: 25 mg	Merchan et al.163
—	Bevacizumab	Everolimus	Bevacizumab: 10 mg Everolimus: 10 mg	Hainsworth et al.164
Sorafenib	Bevacizumab	—	Sorafenib: 200 mg Bevacizumab: 5 mg	Sosman et al.165
Sorafenib		Temsirolimus	Sorafenib: 200 mg Temsirolimus: 25 mg	Patnaik et al.166
Sorafenib		Everolimus	Sorafenib: 400 mg Everolimus: 5 mg	Cen et al.167

Abbreviations: mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.